Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition.

Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read in this material. Trademarks "Freedom" is a registered trademark of SynCardia Systems, LLC. "SynCardia Systems", the SynCardia logo, the Picard logo, "Giving the Gift of Time", "Saving Lives, one Heart at a Time", "Companion 2 Driver " are trademarks of SynCardia Systems, LLC.

EU and international approvals are pending. For additional information and label information, to learn more visit us at www.syncardia.com. Medical Advice Disclaimer The information, including but not limited to, text, graphics, images, and other components contained in this material are for informational purposes only. No information in this material is intended to be a substitute for professional medical advice, diagnosis, or treatment.

Provides group counseling assistance and support to individuals who have undergone the surgical implantation of a Total Artificial Heart (TAH) , while also recognizing the crucial role families and caregivers play in the recovery process. Extending Lifespan and Enhancing Quality of Life Sources: Unique Beating Hearts, Cedars - Sinai Heart Institute & SynCardia Systems, LLC SynCardia's products are approved for sale in the U.S. and Canada only.

Lev'Veon's Story: Courage, Innovation, and a Lifesaving First Age: 10 years old Diagnosis: Myocarditis Implanted: September 6, 2024 Transplanted: September 30, 2024 24 days of Support on the STAH Mott Children's Hospital First STAH Implant SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc.

(2) Carrier, Michel et al.; The Journal of Heart and Lung Transplantation, Volume 40, Issue 3, 220 - 228 (3) SynCardia Systems LLC information Longest Living patient on the STAH 3 SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. SynCardia Systems, LLC.

The STAH is intended to replace a failing or failed human heart in patients with advanced stage heart failure and in need of a heart transplant The STAH is available in two sizes and comes with Hospital and Portable Home Drivers. Backpack - wearable device C2 Driver for Use in Hospital Freedom Driver for Home Use Total Artificial Heart Source: SynCardia Systems, LLC 20 Years of Leadership: From First FDA Approval to Future Innovation - Proven Legacy in Total Artificial Hearts FDA approves Companion C2 Driver FDA approves Freedom Driver FDA approves 50cc STAH US Patents covering fully implantable artificial hearts Patient Hospitalized Patient Mobile in Hospital Patient Mobile in Home Children & Small Adults Alternative to Heart Transplant 2004 2012 2014 2020 2024 FDA approves 70cc STAH First company to receive TAH approval by FDA Next Generation, driver - less STAH; may seek FDA approval in 2028 Notes: Approval years: 2004 - 70cc ventricles; 2012 - Companion C2 driver; 2014 - Freedom Portable Home driver; 2020 - 50cc STAH ventricles.

A U.S. Army veteran, Bernard holds a bachelor's degree from the University of Arizona, a master's in Accountancy from the University of Phoenix, and an MBA from the Thunderbird School of Global Management. Sources: PMI SEC filings SynCardia Systems, LLC SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc.

He brings over 30 years of finance and accounting experience. Before this role, he served as SynCardia's Controller from February to November 2023. Bernard previously held leadership roles at Golden Vertex Corporation, Asarco LLC, Experis, Embraer Aero Seating Technologies, and Cancer Prevention Pharmaceuticals. He began his career at Deloitte and has worked in both the United States and Japan.

Prior to that, he was SynCardia's Director of Manufacturing and Facilities from 2018 to 2021. Matt has contributed to key development programs, including the 50cc Total Artificial Heart and next - generation pneumatic driver. He brings deep experience in engineering and device development to the role. Matt earned a Bachelor's degree in Mechanical Engineering from Northern Arizona University Bernard was appointed Chief Financial Officer in November 2023.

Patrick brings deep operational and strategic expertise in MedTech and Biotech. Matt was appointed Chief Operating Officer in November 2023. He previously served as SynCardia's Director of Research and Development from May to November 2023. From 2021 to 2023, he held multiple roles at Roche, including Systems Development Lead and Staff Mechanical Engineer.

He has also held C - level roles at MedTech and biotech start - ups in Europe and the U.S., including a U.S. - listed Biotech. Earlier in his career, Patrick held director - level positions on Wall Street. He conducted molecular biology research at MIT and holds degrees from Harvard Medical School and Clark University. He currently chairs the board of Acorai AB and previously served on the board of Scandinavian Real Heart.

Global Reach: Over 2,100 implants performed at hospitals across 27 countries. Life - Saving Technology: Replaces both ventricles and all four valves, providing immediate and complete cardiac output. Scalable Commercial Model: We intend to combine direct sales and distributor partnerships with full clinical and technical support to scale commercially SynCardia's products are approved for sale in the U.S. and Canada only.

This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. The offering will only be made by means of the Registration Statement, of which the preliminary prospectus forms a part.

Before you invest, you should read the prospectus (including the risk factors described therein) and other documents that we have filed with the U.S. Securities and Exchange Commission ("SEC") in their entirety for more complete information about the Company. You may access these documents for free by visiting EDGAR on the SEC website at http://www.sec.gov .

The Company and its respective affiliates, representatives and advisors expressly disclaim any and all liability based, in whole or in part, on such information, errors therein or omissions therefrom. Neither the Company nor any of its respective affiliates, representatives or advisors intends to update or otherwise revise the estimates and other information contained herein to reflect circumstances existing after the date identified on the cover page of this Presentation to reflect the occurrence of future events even if any or all of the assumptions, judgments and estimates on which the information contained herein is based are shown to be in error, except as required by law.

Neither the Company nor any of its subsidiaries, affiliates, representatives or advisors assumes any responsibility for or makes any representation or warranty (express or implied) as to, the reasonableness, completeness, accuracy or reliability of the estimates and information contained herein, which speak only as of the date identified on the cover page of this Presentation.

Food and Drug Administration ("FDA") approvals, and success of the Company's products; the Company's approach and goals with respect to research and development; the Company's expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; changes in applicable laws or regulations; and the outcome of any known and unknown litigation and regulatory proceedings.

Forward - looking statements in this Presentation may include, for example, statements about: the Company's market position, including the belief that SynCardia is a leader in the total artificial heart ("TAH") market, the Company's growth strategy, including strong expected sales growth and the factors driving such growth, future operations, financial position, estimated revenues and losses, projected capex, prospects and plans; the Company's strategic advantages and the impact those advantages will have on future financial and operational results; the implementation, market acceptance, expected timing of patent and U.S.

You are cautioned not to unduly rely on such forward - looking statements when evaluating the information in this Presentation. Such forward - looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward - looking statement to reflect events or circumstances after the date of this Presentation.

These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward - looking statements due to numerous factors, risks, and uncertainties that could cause actual results to differ materially from such estimates or forecasts.

Forward - looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by the use of future dates or words such as "may," "should," "could," "will," "expects," "seeks to," "anticipates," "plans," "believes," "estimates," "intends," "predicts," "projects," "forecast," "potential" or "continue" or the negative of such terms and other comparable terminology.